Jennison Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Jennison Associates’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-690,563	Closed	-$31.4M	–	713
2018 Q2	$31.4M	Sell	690,563 -7,013	-1%	-$341K	0.03%	334
2018 Q1	$36.8M	Buy	697,576 +93,904	+16%	+$5.48M	0.04%	298
2017 Q4	$41M	Buy	603,672 +3,503	+0.6%	+$245K	0.04%	289
2017 Q3	$49.5M	Sell	600,169 -585,008	-49%	-$46.4M	0.05%	275
2017 Q2	$111M	Buy	1,185,177 +817,677	+222%	+$50M	0.12%	133
2017 Q1	$23.4M	Sell	367,500 -82,747	-18%	-$5.03M	0.03%	405
2016 Q4	$20M	Buy	450,247 +29,517	+7%	+$1.04M	0.02%	410
2016 Q3	$15.2M	Buy	+420,730	New	+$9.03M	0.02%	443
2013 Q3	–	Sell	-56,959	Closed	-$3.81M	–	723
2013 Q2	$3.81M	Buy	+56,959	New	+$2.56M	﹤0.01%	499

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Jennison Associates's CLVS Position: Q3 2018 in Review

Jennison Associates sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 690,563 shares — an estimated $31.4M sold.

Jennison Associates first reported a position in CLVS in Q2 2013 and held it in 9 quarters. The position peaked at $111M in Q2 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

Jennison Associates reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
Jennison Associates sold 690,563 Clovis Oncology, Inc. shares in Q3 2018, an estimated $31.4M.
Jennison Associates first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 9 quarters.
Jennison Associates's Clovis Oncology, Inc. position peaked at $111M in Q2 2017.
192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.